ETFs Holding IMDZ »    IMDZ Historical Stock Prices »
IMDZ News Video: Tue, Jul 11, 2017, 10:36 AM — Tuesday 7/11 Insider Buying Report: DLTR, IMDZ

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Immune Design is a late-stage immunotherapy company. Co. is focused on oncology and has designed its technologies to activate the immune system's ability to create tumor-specific cytotoxic T cells to fight cancer via distinct mechanisms. Co.'s primary product candidates are CMB305 and G100. CMB305 is a prime-boost cancer vaccine targeting the NY-ESO-1 tumor antigen, in which a prime called LV305 from Co.'s ZVex® platform is dosed sequentially with a boost from Co.'s GLAAS® platform. G100 activates both innate and adaptive immunity in the tumor microenvironment, including dendritic cells, to create an immune response against the tumor's set of antigens, including neoantigens. Self directed investors in Immune Design Corp will be interested in keeping up with all Immune Design Corp news they can find, both IMDZ news originating from the company in the form of press releases, as well as seeing how independent media outlets are reporting news on IMDZ. At RediNews, we simplify this task by presenting both IMDZ news releases originating from Immune Design Corp itself, and IMDZ news from a variety of media outlets. Visitors can browse this news online and through our IMDZ RSS news feed.


IMDZ News — Articles, Videos, & Press Releases

The Zacks Analyst Blog Highlights: Merck, Design, Roche and AbbVie
Monday, February 25, 2019, 8:59 AM — Zacks
Merck to Buy Immunotherapy Developer Immune Design for $300M
Friday, February 22, 2019, 4:08 PM — Zacks
Immune Design Corp Reaches Analyst Target Price
Friday, February 22, 2019, 9:57 AM — ETF Channel
Noteworthy Thursday Option Activity: IMDZ, TTEC, ICPT
Thursday, February 21, 2019, 3:17 PM — Stock Options Channel
First Week of IMDZ June 2019 Options Trading
Thursday, October 25, 2018, 11:07 AM — Stock Options Channel
Noteworthy Friday Option Activity: IMDZ, IBM, CCS
Friday, October 12, 2018, 3:19 PM — Stock Options Channel
Russell 2000 Headed 15% Higher, If Analysts Got The Components Right
Wednesday, October 3, 2018, 8:01 AM — ETF Channel
The Math Shows EQWS Can Go To $54
Friday, August 31, 2018, 9:17 AM — ETF Channel
First Week of March 2019 Options Trading For Immune Design (IMDZ)
Thursday, August 16, 2018, 10:34 AM — Stock Options Channel
Commit To Purchase Immune Design Corp At $2.50, Earn 6.4% Annualized Using Options
Tuesday, July 31, 2018, 11:49 AM — Stock Options Channel
Peek Under The Hood: IWO Has 10% Upside
Friday, July 27, 2018, 7:32 AM — ETF Channel
IMDZ Makes Bullish Cross Above Critical Moving Average
Monday, July 2, 2018, 4:48 PM — Market News Video
The Math Shows IWV Can Go To $180
Tuesday, June 26, 2018, 7:49 AM — ETF Channel
IMDZ is categorized under the Healthcare sector; below are links to news for some other companies in the same sector:


RSS news feeds from RediNews are an ideal complement to other financial content on your market-focused website like stock quotes and charts. our news gives your users what they want — to see what is being published about the stocks they own, and what the companies themselves are publishing. Simply navigate to any RediNews news page by specific ticker symbol, then click the RSS icon for any news page to reach the associated RSS feed (the icon will look like this): . These feeds are made available to you free if charge. We also offer news by broad sector, and a feed of all recent stock news.

IMDZ News | | Copyright © 2013 - 2019, All Rights Reserved

Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.